NGM — NGM Biopharmaceuticals Income Statement
0.000.00%
Last trade - 00:00- $128.53m
- -$15.65m
- $4.42m
Annual income statement for NGM Biopharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 104 | 87.4 | 77.9 | 55.3 | 4.42 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 153 | 191 | 199 | 222 | 156 |
| Operating Profit | -49.3 | -104 | -121 | -166 | -151 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -42.8 | -102 | -120 | -163 | -142 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -42.8 | -102 | -120 | -163 | -142 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -42.8 | -102 | -120 | -163 | -142 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -42.8 | -102 | -120 | -163 | -142 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.639 | -1.5 | -1.56 | -2.03 | -1.73 |
| Dividends per Share |